People | October 07, 2022
Lupin appoints Dr. Shahin Fesharaki as Global Chief Scientific Officer
Dr. Fesharaki most recently served as the Chief Scientific Officer and Global Head of R&D for Hikma Pharmaceuticals.
Dr. Fesharaki most recently served as the Chief Scientific Officer and Global Head of R&D for Hikma Pharmaceuticals.
Transformation to pure-play Innovative Medicines company nears completion
Celgene agreed to provide Dr. Reddy's with a license to sell volume-limited amounts of generic lenalidomide capsules in the U.S.
This launch builds upon Hikma’s leading position as one of the largest US providers of nasally administered medicines used for treating seasonal allergies and advances its objective of growing its specialty business in the US
Sandoz is planned to be incorporated in Switzerland and to be listed on the SIX Swiss Exchange, with an American Depositary Receipt (ADR) program in the US
Carbamazepine Tablets are indicated for use as an anticonvulsant drug and in the treatment of the pain associated with true trigeminal neuralgia
Pharmaceutical sales de-grew 18% YoY and stood at Rs. 224 crore whereas Crop Protection sales de-grew by 15% at Rs. 154 crore
He has over 25+ years of experience in the pharmaceutical Industry and has been working with the company for the past 6 years
Lupin is the 6th largest company in the Indian Pharmaceutical Market
he US FDA has issued six observations pursuant to the completion of the audit.
Subscribe To Our Newsletter & Stay Updated
